nucynta ir tablets 50 mg
mundipharma pharmaceuticals pte. ltd. (uen 200411241w) - tapentadol hydrochloride 58.24 mg eqv tapentadol - tablet, film coated - 50 mg - tapentadol hydrochloride 58.24 mg eqv tapentadol 50 mg
palexia 50 mg film-coat. tabl.
grunenthal sa-nv - tapentadol hydrochloride 58,24 mg - eq. tapentadol 50 mg - film-coated tablet - 50 mg - tapentadol hydrochloride 58.24 mg - tapentadol
palexia retard 50 mg tabl. prol.-rel.
grunenthal sa-nv - tapentadol hydrochloride 58,24 mg - eq. tapentadol 50 mg - prolonged-release tablet - 50 mg - tapentadol hydrochloride 58.24 mg - tapentadol
palexia retard 150 mg tabl. prol.-rel.
grunenthal sa-nv - tapentadol hydrochloride 174,72 mg - eq. tapentadol 150 mg - prolonged-release tablet - 150 mg - tapentadol hydrochloride 174.72 mg - tapentadol
palexia retard 250 mg tabl. prol.-rel.
grunenthal sa-nv - tapentadol hydrochloride 291,2 mg - eq. tapentadol 250 mg - prolonged-release tablet - 250 mg - tapentadol hydrochloride 291.2 mg - tapentadol
nucynta er- tapentadol hydrochloride tablet, film coated, extended release
depo nf sub, llc - tapentadol hydrochloride (unii: 71204kii53) (tapentadol - unii:h8a007m585) - tapentadol 50 mg - nucynta er (tapentadol) is indicated for the management of: - pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate - neuropathic pain associated with diabetic peripheral neuropathy (dpn) severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. limitations of use - because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses, and because of the greater risks of overdose and death with extended-release opioid formulations [see warnings and precautions (5.1)] , reserve nucynta er for use in patients for whom alternative treatment options (e.g., non-opioid analgesics or immediate-release opioids) are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain. - nucynta er is not indicated as an as-needed (prn) analgesic. nucynta er is contraindicated in patients with: - sign
nucynta- tapentadol hydrochloride tablet, film coated
depo nf sub, llc - tapentadol hydrochloride (unii: 71204kii53) (tapentadol - unii:h8a007m585) - tapentadol 50 mg - nucynta (tapentadol) tablets are indicated for the management of acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate in adults. limitations of use because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses [see warnings and precautions (5.1)] , reserve nucynta tablets for use in patients for whom alternative treatment options [e.g., non-opioid analgesics or opioid combination products: - have not been tolerated, or are not expected to be tolerated, - have not provided adequate analgesia, or are not expected to provide adequate analgesia nucynta tablets are contraindicated in patients with: - significant respiratory depression [see warnings and precautions (5.3)] - acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment [see warnings and precautions (5.6)] - known or suspected gastrointestinal obstruction, including suspected paralytic ileus [see warnings and precautions (5.
tapentadol 50mg modified-release tablets
krka uk ltd - tapentadol - modified-release tablet - 50mg
tapentadol 50mg modified-release tablets
alliance healthcare (distribution) ltd - tapentadol - modified-release tablet - 50mg
tapentadol 50mg modified-release tablets
viatris uk healthcare ltd - tapentadol - modified-release tablet - 50mg